Newborn affected by maternal antineoplastic chemotherapy
ICD-10 P04.11 is a billable code used to indicate a diagnosis of newborn affected by maternal antineoplastic chemotherapy.
Newborns affected by maternal antineoplastic chemotherapy may present with a range of complications due to the exposure to cytotoxic agents during gestation. These agents can cross the placenta and affect fetal development, leading to potential neonatal issues such as low birth weight, growth retardation, and hematological abnormalities. The impact of chemotherapy on the newborn can vary based on the timing of exposure, the specific drugs used, and the duration of treatment. Common clinical manifestations include immunosuppression, increased risk of infections, and potential organ dysfunction. Neonates may also exhibit withdrawal symptoms if the mother was on certain medications. It is crucial for healthcare providers to monitor these infants closely for any signs of complications and to provide appropriate supportive care. Documentation should include maternal history of chemotherapy, specific drugs administered, and any observed neonatal complications to ensure accurate coding and management.
Detailed records of maternal chemotherapy, neonatal assessments, and any interventions performed.
Neonates presenting with low birth weight, signs of infection, or hematological issues in the NICU.
Close monitoring for withdrawal symptoms and complications related to immunosuppression.
Comprehensive history of maternal drug use and any ongoing pediatric assessments.
Pediatric follow-up for developmental delays or health issues stemming from in utero exposure.
Consideration of long-term effects of maternal chemotherapy on child development.
Used for initial assessments of newborns affected by maternal chemotherapy.
Document maternal history and any immediate neonatal complications.
Neonatologists should ensure comprehensive evaluations are performed.
Documentation should include a detailed maternal history of chemotherapy, specific drugs used, timing of exposure, and any observed neonatal complications. Additionally, ongoing assessments and interventions for the newborn should be recorded to ensure accurate coding.
